Shire is considering a bid for New Jersey-based NPS Pharmaceuticals, FT Alphaville reported on Friday citing sources. Shire has been working with advisers and held internal discussions about a potential cash offer for NPS, a rare disease specialist, valuing the business at just over $4 billion, the Financial Times blog said.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”